Evasion mechanisms to tumor necrosis factor α (TNF-α) of small cell lung carcinoma and non-small cell lung carcinoma cell lines: Comparison with the erythroleukaemia K-562 cell line

Lung Cancer

Volumn 27, Issue 3, 2000, Pages 177-187

  Sullivan López González, José ^a   Hernández García, Alejandro ^a   Isabel Ponce Noyola, María ^a   Aguilar Cázares, Dolores ^a   José Mandoki, Juan ^b   Medina Morales, Frumencio ^a   Cervera Mendieta, Isabel ^a   Villalba Caloca, Jaime ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Erythroleukaemia; Flow cytometry 1; NSCLC cell lines; SCLC cell line; Sensitivity to TNF ; TNF production; TNF receptors

Indexed keywords

MITOMYCIN C; RECEPTOR SUBTYPE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CELL SPECIFICITY; CELL STRAIN K 562; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ERYTHROLEUKEMIA CELL; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MONOCYTE; PRIORITY JOURNAL;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; COCULTURE TECHNIQUES; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LUNG NEOPLASMS; LYMPHOMA, LARGE-CELL; MONOCYTES; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034160116     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00109-9     Document Type: Article

References (38)

1. Ziegler-Heitbrock H.W.L. The biology of the monocyte system. Eur. J. Cell. Biol. 49:1989;1-12.
2. McBride W.H. Phenotype and functions of intratumoral macrophages. Biochem. Biophys. Acta. 865:1986;27-41.
3. Klostergaard J., Leroux M.E., Hung M.C. Cellular models of macrophage tumoricidal effector mechanisms in vitro: characterization of cytolytic responses to tumor necrosis factor and nitric oxide pathways in vitro. J. Immunol. 147:1991;2802-2808.
4. Nathan C.F., Murray H.W., Cohm Z.A. The macrophage as an effector cell. N. Engl. J. Med. 303:1980;622-626.
5. Gerrard T.L., Terz J.J., Kaplan A.M. Cytotoxicity to tumour cells of monocytes from normal individuals and cancer patients. Int. J. Cancer. 26:1980;585-593.
6. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
7. Beutler B., Cerami A. The biology of cachectin /TNF: a primary mediator of the host response. Ann. Rev. Immunol. 7:1989;625-655.
8. Vilcek J., Lee T.H. Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. J. Biol. Chem. 266:1991;7313-7316.
9. Tartaglia L.A., Weber R.F., Figari I.S., Reynolds C., Palladino M.A. Jr, Goeddel D.V. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA. 88:1991;9292-9296.
10. Gruss H.J., Dower S.K. The TNF ligand superfamily and its relevance for human diseases. Cytokines. Mol. Therapy. 1:1995;75-105.
11. Coffey R.J., Shipley G.D., Moses H.L. Production of transforming growth factors by human colon cancer lines. Cancer Res. 46:1986;1164-1169.
12. Torre-Amione G., Beauchamp R.D., Koeppen H. et al. A highly immunogenic tumor transfected with a murine transforming growth factor type b1 cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA. 87:1990;1486-1490.
13. Vose B.M. Cytotoxicity of adherent cell associated with some human tumours and lung tissues. Cancer Immunol. Immunother. 5:1978;173-179.
14. Takeo S., Sugimachi K., Nagashima A., Nakahashi H., Sugimachi K., Nomoto K. Role of tumor-associated macrophages in lung cancer. Cancer Res. 46:1986;3179-3182.
15. vanRavenswaay C.H.H., Kluin P.M., Fleuren G.J. Tumor infiltrating cells in human cancer: on the possible role of CD16+ macrophages in antitumor cytotoxicity. Lab. Invest. 67:1992;166-174.
16. Sugarman B.J., Aggarwal B.B., Figari I.S., Palladino M.A. Jr, Shepard H.M. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science. 230:1985;943-945.
17. Browning J., Ribolini A. Studies on the differing effects of tumor necrosis factor and lymphotoxin on the growth of several human tumor lines. J. Immunol. 143:1989;1859-1867.
18. Spriggs D.R., Imamura K., Rodriguez C., Sariban E., Kufe D.W. Tumor necrosis factor expression in human epithelial tumor cell lines. J. Clin. Invest. 81:1988;455-460.
19. Beissert S., Bergholz M., Waase I. et al. Regulation of tumor necrosis factor gene expression in colorectal adenocarcinoma: in vivo analysis by in situ hibridization. Proc. Natl. Acad. Sci. USA. 86:1989;5064-5068.
20. Wu S., Boyer C.M., Whitaker R.S. et al. Tumor necrosis factor α as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor α expression. Cancer Res. 53:1993;1939-1944.
21. Spriggs D., Imamura K., Rodriguez C., Horiguchi J., Kufe D.W. Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc. Natl. Acad. Sci. USA. 84:1987;6563-6566.
22. Aderka D., Engelmann H., Hornik V. et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 51:1991;5602-5607.
23. Oliff A., Defeo-Jones D., Boyer M. et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell. 50:1987;555-563.
24. Madsen M., Johnsen H.E. A methodological study of E-rosette formation using AET-treated sheep red blood cells. J. Immunol. Methods. 27:1979;61-74.
25. Islam L.N., Wilkinson P.C. Evaluation of methods for isolating human peripheral blood monocytes. J. Immunol. Methods. 121:1989;75-84.
26. Perry R., Kelley D. Inhibitor of RNA synthesis by actinomycin D: characteristic dose-response of different RNA species. J. Cell. Physiol. 76:1970;127-140.
27. Flick D., Gifford G. Comparation of in vitro cell cytotoxic assays for tumor necrosis factor. J. Immunol. Methods. 68:1984;167-175.
28. Sauty A., Mauel J., Philippeaux M.M., Leuenberger P. Cytostatic activity of alveolar macrophages from smokers and nonsmokers: role of interleukin-1β, interleukin-6, and tumor necrosis factor-α Am. J. Respir. Cell. Mol. Biol. 11:1994;631-637.
29. Kiczka W., Szkaradkiewics A. Suppression of monocyte-mediated anti-K562 cytotoxicity by soluble factors in the serum of cancer patients and in the supernatant of K562 cell culture. Immunol. Lett. 13:1986;127-131.
30. Brockhaus M., Schoenfeld H.J., Schlaegr E.J., Hunziker W., Lesslauer W., Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibody. Proc. Natl. Acad. Sci. USA. 87:1990;3121-3127.
31. Santamaria P., Gehrz R.C., Bryan M.K., Barbosa J.J. Involvement of class II MHC molecules in the LPS-induction of IL-1/TNF secretions by human monocytes: quantitative differences at the polymorphic level. J. Immunol. 143:1989;913-922.
32. Leung K.H., Fischer D.G., Koren H.S. Erythromyeloid tumor cells (K562) induced PGE synthesis in human peripheral blood monocytes. J. Immunol. 131:1983;445-449.
33. Kunkel S.L., Spengler M., May M.A., Spengler R., Larrick J., Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J. Biol. Chem. 263:1988;5380-5384.
34. Janicke R., Mannel D.N. Distinct tumor cell membrane constituents activate human monocytes for tumor necrosis factor synthesis. J. Immunol. 144:1990;1144-1150.
35. DeMarco R., Ensor J.E., Hasday J.D. Tumor-stimulated release of tumor necrosis factor-α by human monocyte-derived macrophages. Cell. Immunol. 140:1992;304-318.
36. Munker M., Munker R., Saxton R.E., Koeffler H.P. Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human cancer cell lines. Cancer Res. 47:1987;4081-4085.
37. Giaccone G., Kadoyama C., Maneckjee R., Venzon D., Alexander R.B., Gazdar A.F. Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines. Int. J. Cancer. 46:1990;326-329.
38. Boldin M.P., Mett I.L., Varfolomeev E.E. et al. Self-association of the `death domains' of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J. Biol. Chem. 270:1995;387-391.